Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Videos|January 5, 2022
Sex, Gender Specific Patient Care Can Impact Patient Health Outcomes, Medication Adherence
Rebecca Sleeper, PharmD, FCCP, FASCP, BCPS, of the Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, discusses how a lack of sex and gender specific patient care education can impact a pharmacist’s work with their patients.
Advertisement
Pharmacy Times interviewed Rebecca Sleeper, PharmD, FCCP, FASCP, BCPS, a professor in the Department of Pharmacy Practice and the senior associate dean of curriculum, assessment, and accreditation at the Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, who recently presented at The Sex and Gender Health Education Summit on health care education in relation to supporting better informed sex- and gender-specific patient care across all health care professions.
During the interview, Sleeper discussed how sex- and gender-specific patient care can overlap and inform pharmacy practice, what sex- and gender-specific patient care education can look like, how a lack of sex and gender specific patient care education can impact a pharmacist’s work with their patients, and how sex- and gender-specific patient care education can impact patient health outcomes and medication adherence.
Advertisement
Related to this article
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
4
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
5